You are here

Home » Content

DEVELOPMENT AND CHARACTERIZATION OF CICLOPIROX OLAMINE LOADED BUCCOADHESIVE FILM FOR TREATMENT OF ORAL CANDIDIASIS

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2013

Key Words:

Author NameFaculty of Author
Abstract (2. Language): 
Buccal bioadhesive films, releasing drug in the oral cavity at a slow and predetermined rate, provide distinct advantages over traditional dosage forms. The study was aimed to prepare and evaluate buccal bioadhesive films of Ciclopirox Olamine (CPO) for oral candidiasis. The film was designed to release the drug at a concentration above the minimum inhibitory concentration for a prolonged period of time so as to reduce the frequency of administration of the available conventional dosage forms and increase patient compliance. The different proportions of various bioadhesive polymers were used for the preparation of films. The films were prepared by solvent casting method and evaluated for various physicochemical properties, bioadhesion, in vitro drug release and effectiveness against Candida albicans. In vitro drug release from the film was determined using a modified Franz diffusion cell while bioadhesiveness was evaluated with an in house developed device. Films containing HPMC K4MC (3%) /Na CMC (1%) was found to be the best with moderate swelling along with favorable bioadhesion force, residence time and in vitro drug release. The microbiological studies revealed that drug released from the film could inhibit the growth of C. albicans for 8 h. The drug release mechanism was found to follow anomalous diffusion. The results of short term stability study revealed stable characteristics of CPO buccal film.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastrmx_160852_3_pp_360-365.pdf
  • 1
360-365
  • English

REFERENCES

References: 

1. A. N. Ellepola, and L. P. Samaranayake. Antimycotic
agents in oral candidiasis: an overview: Clinical
variants, Dent. Update. 27: 111–116 (2000).
2. H. A. Albougy and S. Naidoo. A systematic review of
the management of oral candidiasis associated with
HIV/AIDS, SADJ. 57:457–466 (2002).
3. E. D. Pienaar, T. Young, and H. Holmes.
Interventions for the prevention and management
of oropharyngeal candidiasis associated with HIV
infection in adults and children, Cochrane Database
Syst. Rev. 3: CD003940 (2006).
4. E. Anaissie. Opportunistic mycoses in the
immunocompromised host: experience at a cancer
center and review, Clin. Infect. Dis. 14 (suppl 1):
S43–S53 (1992).
5. J. V. Roey, M. Haxaire, M. Kamya, I. Lwanga, and E.
Katabira. Comparative efficacy of topical therapy
with a slow release mucoadhesive buccal tablet
containing miconazole nitrate versus systemic
therapy with ketoconazole in HIV-positive patients
with oropharyngeal candidiasis, J. Acquir. Immune
Defic. Syndr. 35: 144–150 (2004).
6. S. Bouckaert, and J. P. Remon. In-vitro bioadhesion
of a buccal, miconazole slow release tablet, J. Pharm.
Pharmacol. 45: 504–507 (1993).
7. T. Save and P. Venkitachalam. Buccoadhesive tablets
of nifedipine in standardization of a novel
buccoadhesive erodible carrier, Drug Dev. Ind.
Pharm. 20: 3005–3014 (1994).
8. S. Singh, S. Jain, M. S. Muthu, S. Tiwari, and R. Tilak.
Preparation and Evaluation of Buccal Bioadhesive
Films Containing Clotrimazole, AAPS PharmSciTech,
Vol. 9, No. 2, (2008).
9. N. A. Nafee, F. A. Ismail, N. A. Boraie, and L. M.
Mortada. Mucoadhesive buccal patches of
miconazole nitrate: in vitro/in vivo performance
and effect of ageing, Int. J. Pharm. 1–2: 1–14 (2003).
10. B. Parodi, E. Russo, G. Caviglioli, S. Cafaggi, G.
Bignardi. Development and characterization of a
buccoadhesive dosage form of oxycodone
Milan et al., ARPB, 2013; Vol 3 (I) ISSN 2250-0774
(RESEARCH ARTICLE)
365 | P a g e w w w . a r p b . i n f o
hydrochloride, Drug Dev. Ind. Pharm. 22: 445-50
(1996).
11. K. K. Peh, and C. F. Wong. Polymeric films as vehicle
for buccal delivery: swelling, mechanical, and
bioadhesive properties, J. Pharm. Pharmaceut. Sci.
2: 53–61 (1999).
12. R. Gurny, J. M. Meyer and N. A. Peppas. Bioadhesive
intraoral release systems: design, testing and
analysis, Biomaterials 5: 336-340 (1984).
13. A. Gursoy, I. Sohtorik, N. Uyanik and N. A. Peppas.
Mucoadhesive controlled release systems for
vaginal delivery, STP Pharma 5: 886-892 (1989).
14. G. Levy. Effect of certain tablet formulation factors
on dissolution rate of the active ingredients, J.
Pharm. Sci., 52: 1039-51 (1963).
15. M. S. El-Samaligy, S. A. Yahia, E. B. Basalious.
Formulation and evaluation of diclofenac sodium
buccoadhesive discs, Int. J. Pharm. 286: 27-39
(2004).
16. R. Khanna, S. P. Agarwal, and A. Ahuja.
Mucoadhesive buccal tablets of clotrimazole for oral
candidiasis, Drug Dev. Ind. Pharm. 23: 831–837
(1997).
17. M. R. Rachh, B. S. Barot, P. B. Parejiya, P. K. Shelat
and S. S. Deshpande. Formulation and
Characterization of Ciclopirox olamine
mucoadhesive effervescent tablets for vaginal
delivery, International Journal of Pharmaceutical
Sciences and Nanotechnology. Vol. 5 (4): 1903-
1913 (2013).
18. P. B. Parejiya, B. S. Barot, H. K. Patel, P. K. Shelat, A.
K. Shukla. Development of platform technology for
oral controlled delivery of highly water soluble
drugs using milnacipran HCl as a model drug, Drug
Deliv Lett, 2 (1): 35-45 (2012).
19. S. Anlar, Y. Capan, A. Hincal. Physico-chemical and
bioadhesive properties of polyacrylic acid polymers,
Pharmazie, 48: 285- 7 (1993).
20. N. A Nafee, F. A. Ismail, N. A. Boraie, L. M. Mortada.
Mucoadhesive buccal patches of miconazole nitrate:
in vitro/in vivo performance and effect of ageing,
Int. J. Pharm., 264: 1-14 (2003).
21. C. F. Rodriguez, N. Bruneau, J. Barra, D. Alfonso, E.
Doelker. In Handbook of Pharmaceutical Controlled
Release Technology, Wise, D. L., Ed.; Marcell Dekker:
New York, 2000, Vol. 1, pp. 1-30.

Thank you for copying data from http://www.arastirmax.com